Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caspofungin Prophylaxis for Invasive Candidiasis in High-Risk ICU Adults
NCT00520234Phase 4Completed
- Sponsor
- Mycoses Study Group Education and Research Consortium
- Start
- Aug 2007
- Primary completion
- Mar 2010
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of caspofungin in invasive candidiasis (2 arms), sponsored by Mycoses Study Group Education and Research Consortium. Primary endpoint: Proven and Probable Invasive Candidiasis Based on Modified Mycoses Study Group/European Organization for Research and Treatment of Cancer (MSG/EORTC) Criteria. Started Aug 2007; status: completed.
02
Drugs
caspofungin
03
Conditions
invasive candidiasis
Beyond the preview
Go deeper on NCT00520234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00520234.